Correlation Between Bristol Myers and CureVac NV

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and CureVac NV at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and CureVac NV into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and CureVac NV, you can compare the effects of market volatilities on Bristol Myers and CureVac NV and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of CureVac NV. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and CureVac NV.

Diversification Opportunities for Bristol Myers and CureVac NV

-0.06

Correlation Coefficient

Bristol Myers  CureVac NV

Good diversification

The 3 months correlation between Bristol and CureVac is -0.06. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and CureVac NV in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CureVac NV and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with CureVac NV. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CureVac NV has no effect on the direction of Bristol Myers i.e., Bristol Myers and CureVac NV go up and down completely randomly.

Pair Corralation between Bristol Myers and CureVac NV

Considering the 90-day investment horizon Bristol Myers Squibb is expected to under-perform the CureVac NV. But the stock apears to be less risky and, when comparing its historical volatility, Bristol Myers Squibb is 3.21 times less risky than CureVac NV. The stock trades about -0.01 of its potential returns per unit of risk. The CureVac NV is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  287.00  in CureVac NV on November 29, 2024 and sell it today you would earn a total of  34.00  from holding CureVac NV or generate 11.85% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Bristol Myers Squibb  vs.  CureVac NV

Bristol Myers Squibb

Risk-Adjusted Performance

Very Weak

Over the last 90 days Bristol Myers Squibb has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong primary indicators, Bristol Myers is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

CureVac NV

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in CureVac NV are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather fragile basic indicators, CureVac NV exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Bristol Myers and CureVac NV

The main advantage of trading using opposite Bristol Myers and CureVac NV positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, CureVac NV can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CureVac NV will offset losses from the drop in CureVac NV's long position.

The idea behind Bristol Myers Squibb and CureVac NV pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.